Skip to main content

Table 2 Univariate cox analysis for progression-free survival and overall survival for pediatric EPN_PF

From: Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma

 Progression-free survivalOverall survival
VariableHazard ratio95% CIP valueHazard ratio95% CIP value
Mo. subgroup (EPN_PFA vs. EPN_PFB)8.0121.815–35.3710.00610.8541.446–81.4650.020
5hmC subgroup (high vs. low)3.4381.367–8.6460.0093.0301.192–7.7020.020
Resection (STR vs. GTR)1.3380.602–2.9720.4751.4450.634–3.2920.381
Ki-67 index (≥ 20% vs. < 20%)3.7261.475–9.4270.0051.7870.921–3.4680.086
1q gain (yes vs. no)2.6661.086–6.5480.0323.1481.283–7.7220.012
Age, years (< 4 vs. 4–18)1.5670.678–3.6180.2931.3760.580–3.2620.469
Radiotherapy (yes vs. no)0.6950.281–1.7170.4300.4770.197–1.1590.102
Chemotherapy (yes vs. no)0.8390.334–2.1120.7100.2260.052–0.9850.053
Histology (WHO III vs. WHO II)2.1150.760–5.8850.1512.9380.855–10.1040.087
Gender (male vs. female)1.4160.530–3.7830.4871.0150.400–2.5770.975
  1. P values in italics are of statistical significance
  2. Abbreviations: Mo. molecular, PF posterior fossa, STR subtotal resection, GTR gross total resection, EPN_PFA Group A posterior fossa ependymoma, EPN_PFB Group B posterior fossa ependymoma